Pregabalin is a ligand of alpha2-delta subunit of voltage-gated calcium channels. It reduces the release of neurotransmitters, including glutamate, norepinephrine, serotonin, dopamine, substance P and calcitonin gene-related peptide.

### INDICATIONS:
BONQAT is indicated for alleviation of acute anxiety and fear associated with transportation and veterinary visits in cats.

### DOSAGE AND ADMINISTRATION:
Client Information Sheet is on the reverse of this package insert.

Always provide client information sheet with prescription.

BONQAT is administered orally as a single dose of 5 mg/kg (0.1 mL/kg) approximately 1.5 hours before the start of the transportation or veterinary visit and can be given on two consecutive days. If the cat weighs more than 22 pounds, the total dose will need to be calculated and given in two separate doses as the syringe holds a maximum of 1 mL of solution. A small amount of food can be given with BONQAT.

### CONTRAINDICATIONS:
Do not use in case of hypersensitivity to pregabalin or to any of the excipients (sodium benzoate, ethyl maltol, hydrochloric acid, sodium hydroxide).

### WARNINGS:
**Human Safety Warnings:**
Not for human use.

Appropriate precautions should be taken while handling BONQAT. Avoid skin contact, eye contact, or contact with mucous membranes.

**Adverse reactions** were reported:
- Table 1. Adverse reactions

**CONTRAINDICATIONS:**
- Use with caution in cats with concurrent cardiac disease or hypertension because BONQAT may cause bradycardia and reflex hypertension. The safety of BONQAT has not been evaluated in cats with concurrent cardiac disease or hypertension.
- The safety of use of BONQAT in cats younger than 7 months of age has not been evaluated.
- Use with caution in cats with pre-existing renal disease (See Clinical Pharmacology).
- The safety of use of BONQAT in cats with severe systemic disorder has not been evaluated. Use with caution in cats with severe systemic disorder.

**ADVERSE REACTIONS:**
- Table 1. Adverse reactions

**CONTACT INFORMATION:**
To report suspected adverse events, for technical assistance or to obtain a copy of the SDS, contact Zoetis Inc. at 1-888-963-8471.

**INFORMATION FOR CAT OWNERS:**
Possible side effects on BONQAT include incoordination, tiredness, and vomiting. Some cats might be more sensitive to BONQAT; if the cat appears to be uncoordinated or overly tired, it should be kept warm and not offered food or water until the effect of BONQAT has worn off. This will normally happen within a few hours. If there are further concerns related to side effects after dosing the veterinarian should be contacted.

BONQAT must not be re-dosed if the cat spits part of the dose, vomits after treatment, or in case of hypersalivation, or if BONQAT does not seem to have any effect. Always provide the Client Information Sheet with prescription.

Keep BONQAT in a secure location out of reach of children, dogs, cats, and other animals to prevent accidental ingestion or overdose.

**PHARMACOLOGY:**
Absorption
BONQAT is rapidly absorbed after oral administration in cats. Following oral administration of 5 mg/kg to fasted cats the maximum observed concentration (Cmax) in plasma was 10.1±0.8 (SD) µg/mL and occurred at 0.5-1.0 hours post-dose. The area under plasma concentration time curve from time zero to the last quantifiable time point (AUC(last)) was 199±27 µg.h/mL. The mean absolute oral bioavailability was 94.3%.

Distribution
BONQAT has a relatively large volume of distribution. After intravenous (IV) bolus administration of 2.5 mg/kg, the volume of distribution at the steady state (Vss) was 0.4±0.02 L/kg in cats. BONQAT is not known to bind to plasma proteins in other species, but this has not been studied in cats.

Metabolism and excretion
BONQAT is slowly eliminated from the body of cats. After IV bolus administration of 2.5 mg/kg, total plasma clearance was 0.03±0.008 L/h/kg. The mean half-life of elimination from circulation was 12.3±3.1 hours after IV administration of 2.5 mg/kg and 14.7±2.7 hours after oral administration of 5 mg/kg.

Elimination of the parent compound as well as the methylated metabolite from circulation occurs almost exclusively by renal excretion in other species. This has not been studied in cats.

**Mechanism of Action**
Pregabalin is a ligand of alpha2-delta subunit of voltage-gated calcium channels. It reduces the presynaptic calcium influx in nerves and thereby the release of various neurotransmitters, including glutamate, norepinephrine, serotonin, dopamine, substance P and calcitonin gene-related peptide.

**EFFECTIVENESS:**
The effectiveness of BONQAT was demonstrated in a well-controlled multi-center field study conducted in Europe. A total of 238 cats with a history of being anxious and/or fearful when transported by a car and during veterinary visits were allocated to 1 of 3 treatment groups: 108 cats received BONQAT orally at a dose of 5 mg/kg, 29 cats received BONQAT at a dose of 2.5 mg/kg and 101 cats received placebo (vehicle oral solution containing no active ingredient). The study included assessments during transportation and veterinary examination at a screening visit and a treatment visit. To keep both study visits as similar as possible, all cats were administered tap water prior to the screening visit. Prior to the treatment visit, each cat was administered its randomized treatment. The treatment visit was conducted 5-10 days after the screening visit in a similar manner as the screening visit. Doses were administered approximately 1.5 hours before the cat was put into the carrier and starting of the transportation to the visits. The cats were between 5 months and 15 years of age and weighed 1.8 to 10.3 kg.

Treatment success was defined with 2 primary effectiveness endpoints: the owner’s assessment of the treatment effect based on the cat’s anxiety and/or fear during transportation in a car and the veterinarian’s assessment of the treatment effect based on the cat’s anxiety and/or fear during physical examination at the clinic. These endpoints were based on the following scale (1- Excellent, 2- Good, 3- Fair, 4- Poor, 5- Very Poor).

The treatment effect was statistically significant for both primary effectiveness variables (p = 0.0010) in the group administered BONQAT at the dose 5 mg/kg compared to the placebo group. In the 5 mg/kg group, cat owners assessed the response as excellent or good during the transportation in 54.3% of cases; the corresponding proportion in the placebo group was 27.1%. In the 5 mg/kg group, the veterinarians assessed the response as excellent or good during the clinical examination in 52% of cases; the corresponding proportion in the placebo group was 30%. The 2.5 mg/kg group was not statistically different than placebo for both primary variables.

The owner’s assessment of the treatment successfully improved from screening to treatment visit in the group administered BONQAT at the dose of 5 mg/kg compared to the placebo group. The owner-assessed signs of anxiety and/or fear decreased from screening to treatment visit in the 5 mg/kg group compared to the placebo group. Based on the owners’ observations, vocalization, panting/intense breathing, activity, resistance, and freezing were the signs with the greatest improvement between screening and treatment visits in the 5 mg/kg group. The majority of the cat owners assessed administration of BONQAT as either very easy or easy.

**ADVERSE REACTIONS:**
- Table 1. Adverse reactions

**CONTRAINDICATIONS:**
- Use with caution in cats with concurrent cardiac disease or hypertension because BONQAT may cause bradycardia and reflex hypertension. The safety of BONQAT has not been evaluated in cats with concurrent cardiac disease or hypertension.
- The safety of use of BONQAT in cats younger than 7 months of age has not been evaluated.
- Use with caution in cats with pre-existing renal disease (See Clinical Pharmacology).
- The safety of use of BONQAT in cats with severe systemic disorder has not been evaluated. Use with caution in cats with severe systemic disorder.
- The safety of use of BONQAT in breeding, pregnant, and lactating cats has not been evaluated.

### Summary:
- BONQAT is a well-controlled multi-center field study conducted in Europe.
- Treatment success was defined with 2 primary effectiveness endpoints: the owner’s assessment and the veterinarian’s assessment.
- The treatment effect was statistically significant for both primary effectiveness variables.
- The majority of the cat owners assessed administration of BONQAT as either very easy or easy.

**Table 1. Adverse reactions**

<table>
<thead>
<tr>
<th>Adverse reaction</th>
<th>Pregabalin 5 mg/kg N=108</th>
<th>Pregabalin 2.5 mg/kg N=29</th>
<th>Placebo N=101</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ataxia</td>
<td>5 (4.6%)</td>
<td>1 (3.4%)</td>
<td>0</td>
</tr>
<tr>
<td>Lethargy</td>
<td>3 (2.8%)</td>
<td>2 (6.9%)</td>
<td>0</td>
</tr>
<tr>
<td>Emesis</td>
<td>2 (1.9%)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Proprioception abnormality</td>
<td>1 (0.9%)</td>
<td>1 (3.4%)</td>
<td>0</td>
</tr>
<tr>
<td>Muscle tremor</td>
<td>1 (0.9%)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Anorexia</td>
<td>1 (0.9%)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Weight loss</td>
<td>1 (0.9%)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Mydriasis</td>
<td>0</td>
<td>1 (3.4%)</td>
<td>0</td>
</tr>
</tbody>
</table>
**TARGET ANIMAL SAFETY:**
In a margin of safety study, 32 healthy, 7-month-old Domestic shorthair cats (4/sex/group) were administered a negative control or BONQAT for six consecutive days by once daily oral administration at dose levels of 5, 15, and 25 mg/kg/day. At 5 mg/kg/day, observed signs of sedation included: abnormal gait, slight to moderate uncoordinated behavior, decreased activity, slightly limited usage of hind limbs, lying on side, hypothermia and/or drowsy appearance (i.e. depression, drowsiness, and/or ataxia). Clinical signs of sedation were resolved at the four-hour clinical observation. One male and one female cat had hypothermia observed two to four hours post-dose respectively, the lowest body temperature value was 99°F. Cats had a decrease in heart rate with maximum effect at six hours, but the heart rates stayed within normal range. All adverse observations were resolved by six hours after dosing on the first day of treatment.

At 15 and 25 mg/kg/day, signs of sedation were observed in all cats and included ataxia, lethargy, slightly to moderately limited usage of hind limbs, slight to severe uncoordinated behavior, partially to completely closed eyes, lying on side, dilated pupils, hypothermia, and/or drowsy appearance (i.e. depression, drowsiness, and/or ataxia). On Day 1, all cats had a decreased body temperature at one or more timepoints, the lowest values were 97.8°F when dosed at 15 mg/kg/day and 98.2°F when dosed at 25 mg/kg/day. One cat dosed at 25 mg/kg/day had a loss of consciousness, abnormal gait, eyes closed, decreased activity, lying on side, sedation, salivation, vomiting, hypothermia, and uncoordinated behavior. This cat recovered by the four-hour observation.

Directly after dosing, slight to severe salivation was observed in multiple cats on one or more days. Cats had decreased heart rate with maximum effect at two to six hours, some cats had bradycardia (120-130 bpm). The majority of cats maintained a normal blood pressure, but a few cats with bradycardia had a reflex hypertension. Most adverse observations resolved by eight hours after treatment administration.

In a second margin of safety study, 32 healthy, 1 to 3 years old Domestic shorthair cats (4/sex/group) were administered a negative control or BONQAT for 3 consecutive days by once daily oral administration at dose levels of 5, 15 and 25 mg/kg/day. Directly after dosing, slight to severe hypersalivation was noted in all dose groups. At 5 mg/kg/day, signs of sedation were observed in 6 of 8 cats, and included: abnormal gait, hypothermia, decreased respiratory rate and/or lethargy. These signs were observed between 1 and 6 hours after dosing on the first day of treatment. On Day 2, at six hours post-dose, one cat had muscle tremors that resolved without treatment by the 8-hour observation. Three cats had bradycardia (120-123 bpm) with maximum effect from two to six hours post-dose, but the heart rate remained within the normal range for the other five cats.

At 15 and 25 mg/kg/day, signs of sedation observed in all cats included: ataxia, hypothermia, lethargy, uncoordinated behavior, decreased respiratory rate, and/or they were cold to the touch. The signs of sedation were observed for 12 hours after dosing. One cat in the 15 mg/kg/day dose group had muscle tremors at four hours post-dosing as well as ataxia, lethargy, hypothermia, and a decrease in heart rate. Cats had a decrease in heart rate with maximum effect at two to six hours, a few cats had bradycardia (106-122 bpm). The majority of cats maintained a normal blood pressure, but a few cats with bradycardia had a reflex hypertension. One cat in the 15 mg/kg/day dose group had bradycardia with reflex hypertension at two hours post-dose followed by a reflex tachycardia at six- and eight-hours post-dose.

**STORAGE INFORMATION:**
Store the bottle in a refrigerator at 2-8°C (36-46°F). Use bottle contents within six months after the first day of opening. Up to one month of this time the bottle can be stored at or below 25°C (77°F).

**HOW SUPPLIED:**
BONQAT is packaged in a clear 5 mL glass bottle containing 2 mL of BONQAT (pregabalin oral solution) at 50 mg/mL. The bottle has a child resistant closure and an oral dosing syringe adapter. The bottle is further packed into a carton with a package insert and an oral dosing syringe (1 mL).

Approved by FDA under NADA #141-580

BONQAT® is a trademark of Orion Corporation.

**WHAT IS BONQAT?**
BONQAT is a prescription medicine containing pregabalin. It is used to treat cats afraid of travelling and veterinary visits. BONQAT is a colorless or slightly reddish solution packaged in a clear glass bottle.

**BONQAT can be given with food:**
The product can be given with a small amount of food (e.g. teaspoon of moist food or about ten kibbles of dry food). Water can be freely available.

**When should I administer BONQAT and what should I expect after administering BONQAT?**
BONQAT should be given approximately 1.5 hours before the start of transportation. Your cat should be more relaxed and easier to handle when put into the carrier, during car travel and at the veterinary visit.

**Can I give my cat more than one dose of BONQAT?**
Do not repeat the dose of BONQAT. If the cat spits out part of the dose, vomits after treatment, drools excessively, or BONQAT does not seem to have any effect, contact your veterinarian to discuss further treatment options.

**What are the possible side effects that may occur in my cat after being given BONQAT?**
Possible side effects include incoordination, tiredness, and vomiting. Some cats might be more sensitive to BONQAT; if your cat appears to be uncoordinated or overly tired, keep it warm and do not offer food or water until the effect of BONQAT has worn off. This will normally happen within a few hours. Contact your veterinarian if you have concerns.

**What should I do if I have accidentally given my cat too much BONQAT?**
Contact your veterinarian immediately.

**What if I get BONQAT in my eyes, nose or mouth?**
BONQAT can be absorbed into your body through your eyes or mucous membranes (such as your nose and mouth). If BONQAT comes in contact with your eyes or mucous membranes, flush with plenty of water for 15 minutes. If wearing contact lenses, eyes should be rinsed first, then remove contact lenses and continue rinsing. Seek medical advice if symptoms occur. Symptoms of exposure to BONQAT can include dizziness, sleepiness, blurred vision, weakness, dry mouth, and difficulty with concentration or attention.

**What if I get BONQAT on my skin?**
BONQAT does not absorb through intact skin, but if you have cuts or chapped skin, the drug can be absorbed into your body. In case of skin contact, wash immediately with large amounts of water. Remove contaminated clothing. Contact your physician if you have any questions or concerns. To report side effects, call Zoetis Inc. at 1-888-963-8471.

**What else should I know about BONQAT?**
BONQAT should only be given to the cat for which it was prescribed. This sheet provides a summary of information about BONQAT. If you have any questions or concerns about BONQAT or its effects on your cat, talk to your veterinarian.

**How do I store BONQAT?**
Store the bottle with the dosing syringe and this Client Information Sheet in the carton inside a refrigerator at 2-8°C (36-46°F). Use bottle contents within six months after the first time you open the bottle. Up to one month of this time the bottle can be stored at room temperature (below 25°C (77°F)).

Keep BONQAT out of sight and reach of children and pets at all times.